A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum Tolerated Dose (MTD) and/or recommended phase II dose (RP2D) and schedule of BKM120+GSK1120212
in average 1 year
United States: Food and Drug Administration
|MD Anderson Cancer Center/University of Texas Dept of MD Anderson (8)||Houston, Texas 77030-4009|
|University of California at Los Angeles Div. of Hematology/Oncology||Los Angeles, California 90095|